Current Status And Trends in Ultrasound-Guided Breast Biopsy

https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812
As global breast cancer incidence continues to rise and awareness of early screening grows, the market for ultrasound-guided breast biopsy is entering a period of rapid growth. This niche segment not only impacts the health and well-being of millions of women but has also become a key growth driver in the medical device industry.
From a product perspective, the biopsy needle market exhibits a diversified competitive landscape. International giants such as BD and Mammotome (a subsidiary of Hologic) dominate the high-end segment with their vacuum-assisted biopsy systems, renowned for their high automation levels and superior sample quality. Meanwhile, domestic companies like MicroPort, Weigao, and Kangji are gradually making breakthroughs in the mid-to-low-end biopsy needle market, accelerating import substitution through cost-effective solutions. Particularly in the disposable biopsy needle segment, domestically produced stainless steel and polymer-based needles have already met most clinical requirements.
Technological advancements are reshaping industry dynamics. On one hand, biopsy needles themselves are evolving toward being finer, sharper, and smarter-such as needles with scale markings for easier depth assessment and those coated with ultrasound contrast agents to enhance image clarity. On the other hand, innovations in supporting equipment continue to emerge: the widespread adoption of portable ultrasound devices enables ultrasound-guided breast biopsy procedures in primary healthcare facilities; AI-assisted lesion recognition systems are now beginning to automatically identify optimal needle insertion paths, lowering the operational barrier for practitioners.
The policy environment is providing momentum for industry development. The National Health Commission has included breast cancer screening in the basic public health service program, promoting primary healthcare institutions to equip themselves with ultrasound and biopsy devices. The "Demonstration Project for Application of Domestic Medical Equipment" encourages hospitals to prioritize purchasing domestically produced medical devices, creating broad market opportunities for local companies. Meanwhile, adjustments in medical insurance reimbursement policies are also influencing product selection-some regions have already incorporated ultrasound-guided needle biopsies into disease-based payment models, prompting hospitals to place greater emphasis on cost-effectiveness.
Future trends worth noting include: first, "outpatientization" and "day-case procedures"-as technology advances, an increasing number of biopsies can be performed in outpatient settings, reducing the need for hospitalization; second, "precision" and "minimally invasive approaches"-new biopsy needles will focus more on preserving healthy tissue and minimizing complications; third, "intelligence"-AI will play a growing role throughout the entire process of ultrasound-guided breast biopsy, from lesion detection to needle trajectory planning; fourth, "globalization"-Chinese-made biopsy needles and related equipment are gradually entering international markets, participating in global competition.
It is foreseeable that, driven by demand, technological advancement, and policy support, the industry of ultrasound-guided breast biopsy will continue to expand, contributing more "Chinese solutions" to global breast cancer prevention and treatment efforts.